Multiplikator Forward P/S: Sight Sciences (SGHT)
Sight Sciences, Inc. (SGHT) develops OMNI ophthalmological systems for the implant-free treatment of glaucoma. While electronics supply chain risks constrain expansion, the humanitarian status of the equipment ensures stable global sales. The expected price-to-sales ratio demonstrates asset valuation dynamics, where the value of 6.70 reflects this status, signaling the current momentum of capital inflow into the company.
Ringkesan rincian data analitis Sight Sciences, Inc. (SGHT)
- rega pasar lan target rega analis:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- data utang lan likuiditas:
Total Utang marang Modal Sight Sciences, Inc.|SGHT - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal sightsciences.com|SGHT - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Sight Sciences|SGHT - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Sight Sciences, Inc.|Rasio cepet sightsciences.com
- rincian asil keuangan lan kelipatan valuasi:
SGHT - Penghasilan resik perusahaan|Bathi sing dikarepake Sight Sciences, Inc.|SGHT - Rasio kapitalisasi marang bathi resik|Prakiraan rega marang bathi Sight Sciences Inc|SGHT - Pangali PEG|Pangali EV/EBITDA Sight Sciences, Inc|SGHT - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Sight Sciences, Inc.|SGHT - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan sightsciences.com|SGHT - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Sight Sciences, Inc.
- indikator dodolan lan pendapatan:
Analisis fundamental perusahaan:SGHT (Sight Sciences, Inc)
Steady demand for Sight Sciences (SGHT) ocular microsurgery consumables drives the forward P/S dynamics, reflecting market expectations for revenue scaling. This multiple compares current market capitalization to expected revenue, where elevated values signal an overbought asset, while low values indicate an undervaluation of the innovative tools' potential within future cash flow structures.
Karo sapa Sight Sciences, Inc. saingan
Multiplikator Forward P/S BSX (bostonscientific.com)|EW: Kapitalisasi marang prakiraan pendapatan|ResMed - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Insulet Corporation|ZBH: Multiplikator Forward P/S|COO - Rasio kapitalisasi marang dodolan sing dikarepake|ALGN (Align Corp) - Multiplikator Forward P/S|Globus Medical Corp (GMED) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S TMDX|Multiplikator forward rega marang pendapatan Alphatec Holdings, Inc. ATEC|Multiplikator Forward P/S AORT (artivion.com)|Multiplikator Forward P/S Enovis Corp ENOV|IART - Rasio rega marang prakiraan pendapatan|ESTA: Rasio rega marang prakiraan pendapatan|BBNX (Beta Bionics Inc) - Multiplikator forward rega marang pendapatan|IRADIMED CORPORATION - Rega forward marang dodolan|EMBC (Embecta Health) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tandem Diabetes Care Inc TNDM|Rasio rega marang prakiraan pendapatan AxoGen Inc (AXGN)|SI-BONE, Inc. (SIBN) - Prakiraan rega marang pendapatan|Orthofix Corp - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake bioventus.com (BVS)|OrthoPediatrics Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Treace Medical Concepts Inc TMCI|Strata Critical Medical (SRTA) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CARL (Carlsmed Medical)|Rasio rega marang prakiraan pendapatan rxsight.com|Multiplikator forward rega marang pendapatan ClearPoint Neuro, Inc. (CLPT)|Multiplikator Forward P/S STXS|STIM - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Orchestra BioMed, Inc. OBIO|ANIK: Kapitalisasi marang prakiraan pendapatan|NSPR: Multiplikator forward rega marang pendapatan|Jin Medical - Rasio rega marang pendapatan sing dikarepake|VANI (Vivani Medical Inc) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan XTNT|NMTC (n1mtc.com) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Modular Medical MODD|Rasio rega marang prakiraan pendapatan myomo.com (MYO)|Rasio rega marang prakiraan pendapatan COCH (envoymedical.com)|Rasio rega marang prakiraan pendapatan Vivos Therapeutics Inc VVOS|enVVeno Medical Corp. - Rasio rega marang prakiraan pendapatan|SINT: Multiplikator forward rega marang pendapatan|TNON (Tenon Medical, Inc.) - Kapitalisasi marang prakiraan pendapatan|Lifeward Ltd. (LFWD) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Autonomix (AMIX)|Rasio rega marang prakiraan pendapatan INVO Fertility|Bone Biologics Corp. (BBLG) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan AXNX (Axonics Modulation Technologies)|BIOL (Biolase, Inc.) - Rega forward marang dodolan|Multiplikator Forward P/S DYNT (dynatronics.com)|Rega forward marang dodolan FNA|INVO Bioscience - Multiplikator Forward P/S
